At CPHI Europe, Angela Vollstedt, global director of Cell & Gene Therapies at Novartis discussed scale up strategies for cell ...

Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.

The Cardiovascular and Renal Drugs Advisory Committee voted 10-6 in support of Stealth’s elamipretide for the ultra-rare ...

The US FDA approved Itovebi in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex for certain breast cancer ...

Plaque psoriasis is a chronic condition that affects millions yet is often misunderstood or underappreciated in terms of its ...

XtalPi's AI biologics discovery platform, XtalFold, has been licensed to Janssen Biotech for advanced biotherapeutics ...

Booster Therapeutics has announced its inception to develop a new class of proteasome activator medicines for ...

High-concentration monoclonal antibodies (mAbs) are gaining prominence given the compliance and cost advantages.

Germany-based Merck KGaA has announced the launch of a new €290m ($317.6m) biosafety testing facility in Rockville, Maryland, ...

Pfizer’s former CEO Ian Read and former CFO Frank D’Amelio now back the pharma, despite originally siding with Starboard.

Whilst the events do not outline any new safety risks, the data gives a new understanding of the link between oncogenesis and ...

As a risk factor for future serious health conditions, the early prevention, detection and management of type 2 diabetes are ...